에서 실시간으로 운영 중이에요! 자세히 알아보기
RPRX 아이콘

Royalty Pharma
RPRX

60.96 USD
+1.34
2.25%
장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT
프리마켓
시간외 거래
60.96
0.00
0%
1일
2.25%
5일
6.87%
1개월
4.26%
3개월
4.15%
6개월
25.74%
연초 이후
56.87%
1년
67.75%
5년
64.67%
10년
36.99%
 

소개: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

직원 수: 100

건강관리 생명공학

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 48.3%
중립 48.3%
부정적 3.4%
중립
GlobeNewsWire
23시간 전
Royalty Pharma declares fourth quarter 2026 dividend
NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2026 of $0.235 per Class A ordinary share.
Royalty Pharma declares fourth quarter 2026 dividend
중립
GlobeNewsWire
7일 전
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
긍정적
Zacks Investment Research
8일 전
Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again
긍정적
The Motley Fool
15일 전
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
Royalty Pharma offers exposure to a diversified portfolio of promising drug products and candidates. Its approach provides an optimal way to gain exposure to solid returns with minimal downside risk.
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
긍정적
MarketBeat
22일 전
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
Royalty Pharma NASDAQ: RPRX executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence in China, while maintaining a disciplined approach to capital deployment and leverage.
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
긍정적
The Motley Fool
22일 전
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Revolution Medicines has just received good news around a drug meant to treat pancreatic cancer. While the company has multiple drugs in development, buying Revolution Medicines is still basically like putting all of your eggs in one basket.
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
중립
Seeking Alpha
23일 전
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
중립
GlobeNewsWire
지난달
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
NEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies.
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
중립
Seeking Alpha
지난달
Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
중립
GlobeNewsWire
지난달
Royalty Pharma to present at upcoming investor conferences
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:
Royalty Pharma to present at upcoming investor conferences
뉴스 순위 보기
Lightweight Charts™를 사용해 가격 차트를 구현했어요.